Avicanna And Langara College Team Up For Cannabinoid-Based Translational Research

Author: Vuk Zdinjak | June 13, 2023 09:08am

Avicanna Inc. (OTCQX:AVCNF) (TSX:AVCN) (FSE:0NN) has entered a research collaboration with the Applied Research Centre at Langara College that will focus on Avicanna’s proprietary formulations and pharmaceutical pipeline. This research collaboration has been awarded a peer-reviewed grant from the Natural Sciences and Engineering Research Council of Canada Applied Research and Development Grant for a period of two years starting Q2 2023.

Dr. Jessica Kalra’s group at the Applied Research Centre at Langara College will be collaborating with Avicanna’s R&D team to perform expand in vitro and in vivo research of the company’s drug delivery systems and commercial formulations including under the RHO Phyto brand. The outcomes of the research collaboration would look to gaining a better understanding of the absorption, pharmacokinetic and pharmacodynamic properties of the formulations, which may contribute towards product pipeline developments.

“We are thrilled to be collaborating with Dr. Kalra’s group and look forward to create a deeper understanding of our proprietary cannabinoid formulations which may yield advancements in our drug candidates.” Dr. Frantz Le Devedec, EVP of R&D at Avicanna.

Dr. Kalra, stated: “It is a very exciting time to be researching non-psychoactive pharmaceutically relevant cannabinoids, their impact on the body and how they can be best formulated to provide optimal therapeutic activity. Our team is delighted to have this opportunity to work with Avicanna to support the translation of cannabinoids from bench to bedside.”

Photo: Benzinga edit with photos by geralt and lindsayfox on Pixabay

These 3 Experts Will Help Regulate Rhode Island's Marijuana Market & Other Cannabis Appointments

Vast Majority Of Physicians Have No Idea About Medical Marijuana: Why The Lack Of Interest?

Posted In: AVCNF TSX:AVCN